



Division of Medical Services
Medicaid Pharmacy Program
P.O. Box 1437, Slot S415, Little Rock, AR 72203-1437
P: 501.683.4120 F: 800-424-5851

June 23, 2025

RE: Updates for Tasigna®

Prescribers and pharmacists,

Tasigna® (nilotinib) capsule recently had a generic equivalent enter the market. Effective today, both the generic (nilotinib) and the brand (Tasigna®) will be available for dispensing to Arkansas Medicaid beneficiaries.

Generic nilotinib capsule will require DAW code of zero (0) to process the payment at the correct generic rate. Tasigna® brand capsule will require a DAW code of nine (9) to ensure the claim is processed as a plan prefers brand (PPB) product and pays at the brand rate. **After 7/31/2025**, brand Tasigna® capsule will be considered the plan preferred brand product while the generic will no longer be a preferred option.

Tasigna® follows our oncology policy and requires prior authorization requests to be submitted.

NOTE: This change does not have an impact on nilotinib tartrate that recently became an available product as these products are not interchangeable.

For your convenience, the oncology policy link and oncology medication PA form have been provided.

https://ar.primetherapeutics.com/documents/d/arkansas/oncology_policy_04172024

https://ar.primetherapeutics.com/documents/d/arkansas/ar_oncology_medication_pa_form-1

For any questions, contact the Prime Therapeutics Help Desk at 800-424-7895.

Sincerely,

Cynthia Neuhofel, Pharm.D.
DMS Assistant Director/Pharmacy Director